4.7 Article

Brain Tumor Imaging and Delivery of Sub-5 nm Magnetic Iron Oxide Nanoparticles in an Orthotopic Murine Model of Glioblastoma

Journal

ACS APPLIED NANO MATERIALS
Volume -, Issue -, Pages -

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsanm.2c01930

Keywords

magnetic nanoparticles; iron oxide nanoparticles; sub-5 nm; brain tumor; magnetic resonance imaging; contrast enhancement; enhanced permeability and retention

Funding

  1. National Institutes of Health [R01CA202846, R01CA203388, U01CA198913]

Ask authors/readers for more resources

This study demonstrates the significant advantage of sub-5 nm magnetic iron oxide nanoparticles in targeted therapy of brain tumors. These ultrafine nanoparticles can cross the blood-brain barrier and blood-tumor barrier due to their small core size, leading to efficient accumulation within the tumor. Additionally, sub-5 nm nanoparticles can be visualized using molecular imaging techniques for the detection of brain tumors.
Magnetic iron oxide nanoparticles (IONP) are promising theranostic platforms for cancer imaging and treatment However, delivery of nanoparticles with conventional sizes to intracranial tumors is challenging due to the physiological and biological barriers in the central nervous system. Since advanced glioblastoma (GBM) is highly angiogenic with leaky tumor blood vessels, sub-5 nm ultrafine IONP (uIONP) may preferentially extravasate from the tumor vasculature to exert blood-brain-barrier/blood-tumor-barrier crossing and intratumoral accumulation. Herein, we demonstrate that the renally clearable sub-5 nm oligosaccharide-coated uIONP can efficiently reach intracranial brain tumors in the orthotopic mouse model of GBM after intravenous (i.v.) injection, enabling the visualization of tumors by T-1-weighted magnetic resonance imaging (MRI). Delivery and intratumoral distribution of uIONP are primarily promoted by the enhanced permeability and retention (EPR) effect due to the sub-5 nm core size. uIONP exhibited time-dependent brain tumor uptake with bright T-1-enhanced MRI contrast gradually peaking at 40-60 min after injection. uIONP were compartmentalized in tumor blood vessels at early time points (similar to 20 min), before extravasating and subsequently reaching different areas of tumors (similar to 60 mM) but not in the normal brain tissues. The size advantage of sub-5 nm uIONP in delivery and intratumoral distribution was examined by the comparison between co-injected uIONP and IONP (10 nm core size) labeled with different fluorescent dyes, using MRI, near-infrared (NIR) imaging, fluorescence microscopy, and immunohistochemistry analysis. NIR dye NIR830-labeled uIONP exhibited a sixfold higher penetration and retention in the intracranial tumor than the fluorescein isothiocyanate-labeled IONP with a 10-nm core diameter at 1 h after co-injection. Together, our results demonstrate the sub-5 nm size advantage in delivery of renally clearable nanotheranostics, such as uIONP, for molecular imaging and treatment of brain tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available